KTTA — Pasithea Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Pasithea Therapeutics Selects PAS-003 Lead Development Candidate
Brief: Pasithea Therapeutics Announces Final Results Of Tender Offer
Brief: Pasithea Therapeutics Plans To Commence $4 Mln Tender Offer For Its Common Stock At Price Of $0.70 Per Share In Cash
Brief: Pasithea Therapeutics Receives Letter From Nasdaq Advising Co Granted Extension To Regain Compliance With Listing Requirement
Brief: Pasithea Therapeutics Announces Completion Of GMP Manufacturing For Pas-004
Brief: Pasithea Therapeutics Confirms Receipt Of Unsolicited Proposal From Lucy Scientific Discovery
Brief: Lucy Scientific Discovery Announces Proposal To Acquire Pasithea Therapeutics Corp.
Brief: Pasithea Therapeutics Corp Files Prospectus Related To The Resale Of Up To 16.4 Million Shares By Selling Stockholders - SEC Filing
Brief: Pasithea Therapeutics Corp Files For Mixed Shelf Of Up To $15 Million – SEC Filing
Brief: Pasithea Therapeutics Corp Received Nasdaq Notice Of Delisting
Brief: Pasithea Therapeutics Signs CMC Development And Manufacturing Agreement For The Production Of PAS-004
Brief: Pasithea Therapeutics Announces Comprehensive Settlement Agreement With The Camac Group
Brief: Investor Group Recommends Stockholders Vote The White Proxy Card For Boardroom Change At Pasithea Therapeutics
Brief: Pasithea Therapeutics Postpones Special Meeting Until December 9, 2022
Brief: Investor Group Urges Pasithea Therapeutics Board To Schedule Special Meeting
Brief: Pasithea Therapeutics Corp - Effective Oct 11, Daniel Schneiderman Was Appointed To Serve As The CFO
Brief: Pasithea Therapeutics Acquires Allomek Therapeutics
Brief: Pasithea Therapeutics To Call Special Meeting Of Stockholders
Urges Pasithea Therapeutics To Hold Special Meeting Without Further Delay